Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies (Q37650996)

21 August 2017

title

Role of glucotoxicity and lipotoxicity in the pathophysiology of Type 2 diabetes mellitus and emerging treatment strategies (English)

1 reference

21 August 2017

0 references

1 reference

S Del Prato

1 reference

21 August 2017

publication date

1 December 2009

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

21 August 2017

page(s)

1185-1192

1 reference

Pathogenesis of type 2 diabetes mellitus

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Impact of family history of diabetes on the assessment of beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Deteriorating beta-cell function in type 2 diabetes: a long-term model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Clinical review: the genetics of type 2 diabetes: a realistic appraisal in 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

The new type 2 diabetes gene TCF7L2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Clinical risk factors, DNA variants, and the development of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Genotype score in addition to common risk factors for prediction of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Fasting plasma free fatty acids and risk of type 2 diabetes: the atherosclerosis risk in communities study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

The contribution of hyperglycaemia and hypoinsulinaemia to the insulin resistance of streptozotocin-diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Diabetes associated cell stress and dysfunction: role of mitochondrial and non-mitochondrial ROS production and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Chronic exposure to free fatty acids or high glucose induces apoptosis in rat pancreatic islets: possible role of oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Functional and molecular defects of pancreatic islets in human type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Insulin secretion defects of human type 2 diabetic islets are corrected in vitro by a new reactive oxygen species scavenger

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Hexosamines, insulin resistance, and the complications of diabetes: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Disordered lipid metabolism and the pathogenesis of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Sulfonylurea induced beta-cell apoptosis in cultured human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

The incretin system and its role in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

The role of GLP-1 in the life and death of pancreatic beta cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Thiazolidinediones and insulin resistance: peroxisome proliferatoractivated receptor gamma activation stimulates expression of the CAP gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

beta-cell failure in diabetes and preservation by clinical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Thiazolidinediones improve beta-cell function in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Active sugar transport in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2009.02847.X

10.1111/J.1464-5491.2009.02847.X

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference